Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | UTS2R | Q9UKP6 | 7/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | CYP27B1 | O15528 | 2/20 | 0.41 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1854789 | 0.91 | UTS2R (0.48) | EPHX2NR1H4UTS2RP2RX7SUCNR1 | |
| SCHEMBL1854412 | 0.84 | NR1H4 (0.48) | EPHX2NR1H4UTS2RPRMT5 | |
| SCHEMBL5044326 | 0.81 | P2RX7 (0.49) | EPHX2NR1H4UTS2RP2RX7SUCNR1 | |
| SCHEMBL1853555 | 0.79 | TACR1 (0.53) | EPHX2NR1H4CYP24A1PRMT5 | |
| SCHEMBL5045075 | 0.78 | P2RX7 (0.46) | EPHX2NR1H4UTS2RP2RX7SUCNR1 | |
| SCHEMBL5045759 | 0.77 | UTS2R (0.51) | EPHX2NR1H4UTS2RP2RX7SUCNR1 | |
| SCHEMBL1855533 | 0.76 | GPR139 (0.43) | EPHX2NR1H4MEN1KMT2AKAT6A | |
| SCHEMBL6440695 | 0.75 | ERN1 (0.49) | EPHX2NR1H4UTS2RSUCNR1KAT6A | |
| SCHEMBL5047432 | 0.74 | NR1H4 (0.53) | EPHX2NR1H4PRMT5 | |
| SCHEMBL1855680 | 0.72 | TMEM97 (0.49) | UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592477-B2 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) | LABORATOIRES SERONO SA (CH) | 2009-09-22 | — | — | US | disclosed |
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | APPLIED RESEARCH SYSTEMS ARS (NL) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124656-A1 | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) | PTPRS, PTPA, PTPMT1 | EPHX2 2771/4885NR1H4 1543/4885UTS2R 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.